EU: Stakes High For Novartis At Latest CHMP Meeting
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.